Categories AlphaGraphs, Earnings, Health Care
AngioDynamics (ANGO) reports net loss for Q2 2025; sales drop 8%
AngioDynamics Inc. (NASDAQ: ANGO) reported a net loss for the second quarter of 2025 as the medical device company’s revenues decreased 8%.
Net loss, excluding special items, was $0.04 per share in the November quarter, compared to a loss of $0.05 per share in the corresponding period of 2024. On an unadjusted basis, net loss narrowed to $10.7 million or $0.26 per share in Q2 from $29 million or $0.72 per share in the prior-year quarter.
Revenues, on a reported basis, decreased 8% year-over-year to $72.8 million in the second quarter. The company continues to expect fiscal 2025 sales in the range of $282 million to $288 million.
Commenting on the results, AngioDynamics’ CEO Jim Clemmer said, “We are very excited about our strong performance during the second quarter, and in particular the continued strength of our Med Tech segment,
which grew 25% over the prior year.”
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Important takeaways from Conagra Brands’ Q3 2025 report
Conagra Brands, Inc. (NYSE: CAG) has reported weaker-than-expected revenue and profit for the February quarter, with sales declining across all business segments amid softer demand and persistent supply challenges. The
Main takeaways from Lamb Weston’s (LW) Q3 2025 earnings report
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) jumped 9% on Thursday after the company delivered better-than-expected results for the third quarter of 2025 and reaffirmed its outlook for the
Summary: Tesla (TSLA) reports Q1 2025 production, deliveries
Tesla Inc. (NASDAQ: TSLA) has announced results of vehicle production and deliveries for the first quarter of 2025. The company also provided data on the deployment of energy storage products
